Study 1 of 1ABS-201 literatureExpert opinion on pharmacotherapy · Review2026
Emerging pharmacotherapies for androgenetic alopecia.
Confirms ABS-201 is in clinical development for androgenetic alopecia as a prolactin-receptor-targeting biologic. It contains no data on whether it works.
Where it sits
this study against the rest of the abs-201 corpus0
Preclinical
0
Observational
0
Open-label
0
Randomised
1
Reviews · this one
Summary and findings
A narrative review of emerging drug development for androgenetic alopecia. It lists ABS-201 alongside HMI-115 as biologics targeting prolactin receptor inhibition, within a wider survey of investigational approaches. It reports no efficacy or safety data specific to ABS-201.
How much of this paper we could read: partial text (0.60). We had some abstract detail. Check the source for anything decisive. What this means →
2026
Key findings
- Lists ABS-201 among biologics targeting prolactin receptor inhibition for androgenetic alopecia.
- Surveys the emerging androgenetic alopecia pipeline broadly rather than reporting outcomes for any single agent.
- Reports no efficacy or safety data for ABS-201.
Limitations
A narrative review rather than a study of ABS-201. Its mention of the compound describes development status and does not report any measured outcome, so it establishes that the compound exists and is in development, and nothing more.